When was Biomodal founded?

Biomodal was founded in 2012 and raised its 1st funding round 2 years after it was founded.

Where is Biomodal located?

Biomodal is headquartered in Cambridge, United Kingdom.

Which legal entities is Biomodal associated with?

Biomodal is associated with Cambridge Epigenetix Limited and 2 others.

How many employees does Biomodal have?

As of Jun 30, 2026, the latest employee count at Biomodal is 97.

Is Biomodal a funded company?

Biomodal is a funded company, having raised a total of $164M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Oct 29, 2014.

How much is Biomodal worth?

The latest valuation of Biomodal is $***** as of Apr 02, 2018.

When was the latest funding round of Biomodal?

Biomodal's latest funding was a $***** Series D round on Nov 02, 2021, with participation from 6 investors.

What is the annual revenue of Biomodal?

Annual revenue of Biomodal is between £1M and £10M as on Dec 31, 2024

Where does Biomodal rank among its competitors?

Biomodal ranks 1st amongst 18 active competitors, of which 8 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Epigenica, which secured $2.2M in Jun, 2025.

Who are the top competitors of Biomodal?

Biomodal's top competitors include FOXO Technologies, Moonwalk and Epigenica. Among them, Epigenica secured the most recent funding round in June, 2025.

Biomodal - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of a duet multiomics platform that generates genetic and epigenetic data. It offers a duet multi-omics solution +modC which uses next-generation sequencing and a platform to acquire genetic and epigenetic methylation information. It is used for cancer research, Non-invasive prenatal testing, precision medicine, and others.

Website: biomodal.com
Social
Email ID: *****@biomodal.com
Phone Number: +44 **********

Key Metrics

Founded Year

2012

Location

Cambridge, United Kingdom

Stage

Series D

Total Funding

$164M in 5 rounds

Latest Funding Round

Series D, Nov 02, 2021, $*****

Post Money Valuation

$***** as on Apr 02, 2018

Investors

Google Ventures & 24 more

Ranked

1^st among 18 active competitors

Annual Revenue

£1M - £10M as on Dec 31, 2024

Employee Count

97 as on Jun 30, 2026

Similar Companies

FOXO Technologies & 18 more

View Biomodal's full profile

Biomodal is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Cambridge Epigenetix Ltd CIN: 8005377 , Germany, Active		-	104 (As on Dec 31, 2024)
BIOMODAL INC. CIN: 5451313 , United States, Active	Dec 17, 2013	-	13 (As on Dec 31, 2024)	-
Cambridge Epigenetix Limited CIN: 8005377 , United Kingdom, Active		£1M - £10M (As on Dec 31, 2024)	90 (As on Dec 31, 2023)

Biomodal has raised a total funding of $164M over 5 rounds. Its first funding round was on Oct 29, 2014. Its latest funding round was a Series D round on Nov 02, 2021 for $*****. 6 investors participated in its latest round. Biomodal has 18 institutional investors and 7 angel investors.

Here is the list of recent funding rounds of Biomodal:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 02, 2021	6741517	Series D	9033085	2829584	2902946	9564472
Jan 01, 2020	5384897	Grant (prize money)	5585717	8119839	2725476	Europa
Apr 02, 2018	4400045	Series C	1448186	7553762	Ahren	Sequoia Capital & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Biomodal's funding rounds and investors

Here are the details of Biomodal's key team members:

Peter Fromen: CEO of Biomodal. They serve on the board of 1 company.

Biomodal's Board of Directors

Biomodal's board has 6 active members. Gail Marcus and Peter Fromen are part of team and Omead Ostadan, Peter James Wrighton-smith, Shankar Balasubramanian and Thomas William Hulme are independent board members.

Here is the list of Biomodal's board of directors:

Name	Type	Representing	Status	Duration
suorxd{	Team	-	Current	6y 8m
Gail Marcus	Investor	-	Current	7y 9m
Omead Ostadan	Independent board member	-	Current	3y 11m
rrqfnfb	Independent board member	-	Current	9y 8m
k{kecec	Independent board member	-	Current	3y 6m
b{vgjrx	Independent board member	-	Current	8y 1m

View details of Biomodal's Founder profiles and Board Members

Biomodal's employee count trend

Biomodal has 97 employees as of Jun 26. Here is Biomodal's employee count trend over the years:

Uncover Biomodal's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Biomodal include FOXO Technologies, Moonwalk and Epigenica. Here is the list of Top 10 competitors of Biomodal, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Biomodal 2012, Cambridge (United Kingdom), Series D	Developer of a duet multiomics platform that generates genetic and epigenetic data	$164M	Third Point, Google Ventures & 23 others	63/100
2nd	FOXO Technologies 2020, Minneapolis (United States), Public	Provider of epigenetic biomarkers discovery and development platform	$40M	Bespoke Growth Partners, Inc., Centrecourt Asset Management ... Read more	60/100
3rd	Moonwalk 2022, San Francisco (United States), Series A	Digital platform pioneering precision epigenetic medicines	$57M	Google Ventures, Khosla Ventures & 3 others	60/100
4th	Epigenica 2020, Stockholm (Sweden), Seed	Provider of solutions for the analysis of genomic data	$2.2M	Voima Ventures, Almi Invest & 4 others	46/100
5th	Chroma Medicine 2020, Cambridge (United States), Series B	Developer of an epigenetic editing platform for genomic medicines	$260M	Google Ventures, Atlas Venture & 16 others	45/100
6th	Chronomics 2017, Norwich (United Kingdom), Seed	Provider of an online digital platform for epigenetics data	$1.43M	Anthemis Group, SOSV & 3 others	42/100
7th	Reaction Biology 2001, United States, Late Stage	In vitro enzyme activity assays, secializing in kinase & epigenetic HTS and profiling	-	Cobepa, CYwP Funds & 6 others	40/100
8th	Yijie Like Shanghai (China), Seed	Developer of epigenetic regulation technology to treat a variety of diseases	$14.8M	Morningside, Xicheng Jinrui & 3 others	37/100
9th	Peconic 2012, State College (United States), Unfunded	Provider of precision mapping for epigenomic research	-	-	30/100
10th	Histone Therapeutics 2021, Seattle (United States), Funding Raised	Developer of epigenetic reprogramming therapies for gene activation	-	National Science Foundation	30/100